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The development of B lymphocytes from hema-
topoietic progenitor cells in the BM to mature, 
recirculating B cells can be divided into distinct 
stages according to the expression of specifi  c 
marker proteins and the rearrangement status 
of the Ig H and L chain gene loci (1, 2). Pro-
gression through these stages is tightly regu  lated 
by signal transduction processes derived from 
various receptors in the membrane.
One important checkpoint in B cell devel-
opment is the pre–B cell stage. Productive VDJ 
recombination at the H chain locus leads to the 
expression of μ H chain, which is then assem-
bled with the surrogate L chain components λ5 
and VpreB and the signal-transducing subunits 
Ig-α and -β to form the pre–B cell receptor 
(pre-BCR) (3, 4). Autonomous signaling from 
the pre-BCR on the cell surface induces cell 
division, L chain rearrangement, and subse-
quent diff  erentiation into immature B cells 
  expressing the BCR (5–7). Thus, defects in signal 
transduction in developing B cells may interfere 
with normal development and/or enable uncon-
trolled proliferation, thereby leading to immuno-
defi  ciency, autoimmunity, or leukemia.
Signal transduction from the pre-BCR re-
quires recruitment and activation of the spleen 
tyrosine kinase (Syk) (8, 9). Syk belongs to the 
Syk/ZAP-70 family of nonreceptor kinases and 
is characterized by two N-terminal Src homo-
logy 2 (SH2) domains and a C-terminal kinase 
domain, which are separated by a fl  exible linker 
(9). Syk is activated by (a) binding via its SH2 
domains to phosphorylated   immunoreceptor 
tyrosine-based activation motifs (ITAMs) in 
the cytoplasmic tails of Ig-α and -β, (b) phos-
phorylation through Src family kinases, and 
(c) by autophosphorylation (9). Activated Syk 
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phosphorylates several downstream signaling elements, in-
cluding the adaptor protein SH2 domain–containing leuko-
cyte protein of 65 kD (SLP-65; also known as BLNK or 
BASH) (8, 9). Phosphorylated SLP-65 provides docking sites 
for key signaling proteins such as phospholipase Cγ (PLCγ), 
Vav, Bruton’s tyrosine kinase, and growth factor receptor 
binding protein 2 (10). Binding of these proteins to SLP-65 
nucleates a signaling complex that leads to the activation of 
downstream signaling pathways and the induction of specifi  c 
transcription factors, thereby altering gene expression and 
  determining cell fate (10).
Mutations in genes encoding signaling proteins and trans-
cription factors are frequently involved in malignant trans-
formation and cancer development. For example,  6% of 
SLP-65−/− mice develop leukemia, and loss of SLP-65 was 
correlated to development of leukemia in humans (11–13). 
Although SLP-65 represents a tumor suppressor, several other 
signaling proteins are actively involved in malignant transfor-
mation and are therefore considered protooncogenes. A well-
studied example is the Abelson kinase (Abl). Fusion of the abl 
gene to the break point cluster region in the so-called Phila-
delphia chromosome leads to expression of the deregulated 
Abl protein (designated BCR-Abl) that is found in chronic 
myelocytic leukemia, acute myelocytic leukemia, and acute 
lymphocytic leukemia (ALL) (14). Another example is the 
  transcription factor c-Myc, which regulates the expression of 
genes involved in the proliferation or diff  erentiation of nor-
mal cells and is overexpressed or mutated in a variety of 
  human cancers (15, 16). In Burkitt lymphoma, for instance, 
the myc gene is translocated into the vicinity of the H chain 
enhancer, resulting in deregulated c-Myc expression that 
leads to increased proliferation (17).
Several studies suggest an active role of Syk in cancer de-
velopment. For instance, the TEL-Syk fusion protein was 
isolated from a patient with myelodysplastic syndrome and 
has been shown to transform BaF-3 cells in vitro (18). In this 
case, the dimerization domain of the transcription factor 
translocated ETS leukemia (TEL; also known as ETV6) is 
fused to the linker region of Syk by chromosomal transloca-
tion t(9;12)(q22;p12), thereby leading to constitutive auto-
phosphorylation and activation of Syk (18, 19). A similar 
translocation fusing the N-terminal pleckstrin homology 
(PH) domain and the proline-rich Tec homology domain of 
the inducible T cell kinase (ITK) to the Syk linker region 
was recently isolated from patients with peripheral T cell 
lymphoma (20). In addition, overexpression of Syk was re-
ported in mantle cell lymphoma, and both Syk and ZAP-70 
are expressed in ALL (21–23). Furthermore, expression of 
Figure 1.  Syk enables growth factor–independent proliferation. 
(A) SLP65−/− pre–B cells were retrovirally transduced with IRES-GFP vec-
tors encoding either GFP alone, SLP-65, or Syk. (left) Immunoblot analysis 
for the expression of Syk and SLP-65 in a WT pre–B cell line and trans-
duced SLP-65−/− pre–B cells sorted for GFP expression. (right) Enrichment 
of Syk-expressing cells. The proportion of GFP+ cells in transduced cultures 
was determined by FACS at 1 d and 1 wk after transduction. Data are rep-
resentative of three independent experiments. (B) Syk allows proliferation 
in the absence of IL-7. FACS profi  les showing SLP-65−/− pre–B cells trans-
duced with either GFP or Syk and cultured in the absence of IL-7 for 3 wk. 
Data are representative of fi  ve independent experiments. Numbers repre-
sent the percentage of cells in the indicated quadrant. FSC, forward scatter.JEM VOL. 203, December 25, 2006  2831
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ITAM sequences has been shown to transform epithelial 
cells by a mechanism involving Syk, and overexpression of 
the tumor suppressor PTPROt, a phosphatase regulating 
Syk activity, was shown to block proliferation of B lym-
phoma cells (24–26).
On the other hand, several studies indicate that Syk acts 
as a suppressor of tumor growth and invasiveness in human 
malignancies. For example, although Syk expression was 
found in normal breast tissue and noninvasive breast carcino-
mas, it was not detected in invasive tumors, and its loss has 
been correlated to a poor prognosis for breast cancer patients 
(27–29). Although these results were not confi  rmed by a 
more extensive study, a correlation between loss of Syk and 
metastasis formation was found in gastric cancer, melanomas, 
and a subset of ALL (30–33).
In this paper we address the role of Syk in proliferation 
and diff  erentiation and show that Syk is a protooncogene 
able to transform pre–B cells and that Syk activity is also 
  necessary for the proliferation of other leukemia cells, such as 
those transformed by c-Myc.
RESULTS
Syk transforms pre–B cells in vitro
To investigate the role of Syk in proliferation, we examined its 
eff  ect on pre–B cell proliferation with that of SLP-65, which 
acts as a tumor suppressor in pre–B cells (11–13). Therefore, 
we retrovirally expressed Syk–internal ribosome entry se-
quence (IRES)–GFP or SLP-65–IRES–GFP in SLP-65−/− 
pre–B cell lines and monitored the proliferation of GFP+ 
cells compared with nontransduced, GFP− cells of the same 
Figure 2.  TEL-Syk transforms pre–B cells in vitro. (A) WT pre–B cell 
lines were retrovirally transduced with IRES-GFP vectors encoding either 
GFP alone, TEL-Syk, or BCR-Abl. Cells were cultured in the absence of IL-7 
and analyzed by FACS at days 1 and 4 after transduction. (B) Transforma-
tion of SLP65−/− pre–B cell lines. FACS analysis as described in (A) but 
using SLP65−/− pre–B cells. (C) Transformation of freshly isolated WT BM-
derived pre–B cells. FACS analysis as described in (A) but using freshly 
isolated BM-derived pre–B cells. Data are representative of fi  ve indepen-
dent experiments. Numbers represent the percentage of cells in the indi-
cated quadrant. FSC, forward scatter.2832  SYK KINASE IS A PROTOONCOGENE | Wossning et al.
  culture. In line with previous data showing that SLP-65 regu-
lates proliferation, the proportion of SLP-65–expressing cells 
in such mixed cultures decreased over time (Fig. 1 A). This 
eff  ect was not caused by SLP-65 overexpression because SLP-
65 protein levels were comparable to those in WT cell lines 
(Fig. 1 A). In contrast, Syk-expressing cells were enriched re-
producibly and could be kept in culture for prolonged times, 
whereas Syk protein levels were elevated as compared with 
WT and SLP-65−/− cells (Fig. 1 A). This indicates that Syk 
does not interfere with pre–B cell proliferation and, therefore, 
does not function as a tumor suppressor. Rather, the accumu-
lation of Syk-expressing cells suggested an involvement of Syk 
in the activation of pre–B cell proliferation. Because prolifera-
tion of mouse pre–B cells depends on the presence of IL-7 as 
a growth factor, we determined the ability of Syk to induce 
IL-7–independent proliferation. Withdrawal of IL-7 from 
cultures transduced with GFP alone blocked proliferation of 
both the nontransduced and transduced populations and ulti-
mately led to cell death. In contrast, Syk-expressing cells were 
enriched in cultures without IL-7 and became stable IL-7–
independent lines (Fig. 1 B). Similar results were obtained 
with three out of six tested SLP-65−/− pre–B cell lines and 
one out of three tested WT pre–B cell lines but not with 
freshly isolated BM pre–B cells (unpublished data).
As growth factor independence is one hallmark of cellular 
transformation and is often associated with cancer develop-
ment, these data indicate that deregulated Syk is involved in 
the transformation of pre–B cells.
The TEL-Syk fusion protein transforms pre–B cells in vitro
To provide further evidence for the involvement of deregu-
lated Syk in pre–B cell transformation, we tested whether 
aberrant Syk variants resulting from described chromosomal 
translocations transform pre–B cells. One such Syk variant 
is the TEL-Syk fusion protein, which was isolated from a 
  patient with myelodysplastic syndrome and was shown to be 
constitutively active (18). To test TEL-Syk in pre–B cells, we 
retrovirally transduced freshly isolated BM pre–B cells and 
diff  erent WT and SLP-65−/− pre–B cell lines with a TEL-
Syk–encoding IRES-GFP vector. IRES-GFP vectors encod-
ing GFP alone and the well-studied BCR-Abl oncoprotein 
were used as negative and positive controls, respectively. 
Withdrawal of IL-7 from cultures containing transduced and 
nontransduced cells led to an enrichment of TEL-Syk–
  expressing cells to  90% in all tested cell lines and primary 
BM cultures after 4 d (Fig. 2). Furthermore, nontransduced 
cells were lost from culture, whereas stable IL-7–independent 
lines were obtained from all TEL-Syk–expressing cell lines 
and primary BM cells. Similarly, cells expressing BCR-Abl 
were enriched to  90% of the culture after 4 d without IL-7 
and gave rise to stable lines, whereas cells expressing GFP 
alone died out (Fig. 2).
Collectively, these data show that expression of TEL-
Syk, like that of BCR-Abl, leads to IL-7–independent prolif-
eration and transformation of pre–B cells in vitro, suggesting 
that Syk is, analogous to Abl, a protooncogene.
TEL-Syk–transformed cells induce leukemia in mice
The ability to proliferate in the absence of growth factors is a 
common feature of cancer cells. To test whether TEL-Syk–
expressing pre–B cells are able to induce leukemia in mice, we 
injected a mixture of TEL-Syk–transduced and nontransduced 
pre–B cells from WT BM into the tail vein of alymphoid RAG-
2/γC−/− mice. As controls, we injected a mixture of GFP-
transduced and nontransduced cells or BCR-Abl–transformed 
cells (Fig. 3 A). Mice that received TEL-Syk– or BCR-Abl–
expressing cells showed symptoms of disease and developed 
splenomegaly  3 wk after injection (Fig. 3 B). FACS analysis 
of spleens and BM of these animals revealed high numbers of 
GFP+ CD19+ B cells, whereas GFP− CD19+ B cells were 
completely absent (Fig. 3 C). In contrast, mice that received 
only GFP-transduced cells remained healthy, did not develop 
splenomegaly, and showed no enrichment of GFP+ cells when 
compared with the cultures before injection.
Figure 3.  TEL-Syk–expressing cells cause leukemia upon injection 
in mice. (A) Freshly isolated WT BM-derived pre–B cells (shown in Fig. 2 C) 
were retrovirally transduced with IRES-GFP vectors for the expression of 
either GFP alone, TEL-Syk, or BCR-Abl and injected into the tail vein of 
RAG-2/γC−/− mice. (B) Spleens of the mice 3 wk after injection. (C) FACS 
profi  les showing the expression of GFP and CD19 in cells from the indi-
cated spleens of duplicate mice. Data are representative of fi  ve indepen-
dent experiments. Numbers represent the percentage of cells in the 
indicated quadrant. FSC, forward scatter.JEM VOL. 203, December 25, 2006  2833
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Collectively, these data show that TEL-Syk–expressing 
cells proliferate rapidly in vivo, thereby inducing aggressive 
leukemia, similar to BCR-Abl–transformed pre–B cells.
Syk kinase activity is required for transformation 
of pre–B cells
To test whether TEL-Syk–induced transformation is depen-
dent on Syk kinase activity, we generated a kinase-negative 
mutant of TEL-Syk with a lysine to alanine amino acid 
  replacement at position 402 (TEL-SykK402A) in the ATP 
binding site of the kinase domain (34). Expression of the 
TEL-SykK402A mutant in diff   erent pre–B cell lines and 
BM pre–B cells did not confer IL-7–independent growth 
to these cells, suggesting that Syk kinase activity is required 
for transformation (unpublished data). In line with this, 
TEL-Syk–transformed SLP-65−/− pre–B cells showed strong 
  tyrosine phosphorylation of specifi  c  substrates,  including 
TEL-Syk itself, whereas TEL-SykK402A–expressing cells 
showed reduced phosphorylation, which was comparable to 
that of GFP-expressing cells (Fig. 4 A). Although strong 
  tyrosine phosphorylation of distinct substrates was also ob-
served in BCR-Abl–transformed cells, the phosphorylated 
high molecular mass (>70 kD) proteins diff  ered between 
BCR-Abl– and TEL-Syk–transformed pre–B cells (Fig. 4 A). 
To identify the main high molecular mass substrates for 
TEL-Syk, we immunoprecipitated tyrosine-phosphorylated 
proteins from lysates of TEL-Syk–transformed pre–B cells, 
separated them by SDS-PAGE, and silver stained the gels 
(Fig. 4 B). Analyses of the main bands by mass spectrometry 
revealed that several bands at 80–83 kD correspond to TEL- 
Syk itself and that phosphatidylinositol 3–kinase (PI3-K), 
Cbl, and PLCγ2 are major phosphoproteins in TEL-Syk–
transformed pre–B cells.
The specifi  c Syk inhibitor R406 blocks 
Syk-induced proliferation
Because transformation by TEL-Syk is dependent on Syk 
kinase activity, we wanted to test whether Syk-specifi  c in-
hibitors might be used to block the proliferation of Syk-trans-
formed cells. A substance commonly used for inhibition of 
Syk is piceatannol, while a novel and more specifi  c Syk inhib-
itor is R406 (35–37). To investigate whether these substances 
block the proliferation of Syk-transformed cells, we fi  rst tested 
whether they reduce the specifi  c protein phosphorylation ob-
served in Syk-transformed cells. Therefore, we treated TEL-
Syk–transformed pre–B cells for various times with R406 and 
piceatannol and analyzed the pattern of phosphorylation by 
immunoblotting (Fig. 4 C). As controls, we used the Src fam-
ily kinase inhibitor PP2 and the Abl inhibitor STI-571 (also 
known as Gleevec or Imatinib). Remarkably, phosphoryla-
tion of the majority of proteins was strongly reduced after 
1 min of treatment with R406. Only weakly phosphorylated 
bands corresponding to TEL-Syk itself remained visible at 
60 min, and prolonged incubation with R406 completely 
abolished phosphorylation (Fig. 4 C and not depicted). Simi-
larly, the increased overall tyrosine phosphorylation in cells 
transformed by overexpression of Syk was reduced by R406 
treatment, whereas BCR-Abl–transformed cells were only 
weakly aff  ected by R406 (Fig. S1, available at http://www.
jem. org/cgi/content/full/jem.20060967/DC1). Treatment 
with high concentrations of piceatannol (50 μM) also slightly 
decreased phosphorylation levels, whereas treatment with 
neither PP2 nor STI-571 aff  ected the overall phosphorylation 
in TEL-Syk–transformed cells (Fig. 4 C). Treatment with 
STI-571, however, decreased the phosphorylation levels in 
BCR-Abl–transformed cells (Fig. S1).
Figure 4.  TEL-Syk induces phosphorylation of specifi  c substrates. 
(A) Immunoblot analysis of pre–B cells transduced with IRES-GFP vec-
tors for the expression of either GFP, TEL-Syk, the kinase-negative TEL-
SykK402A, or BCR-Abl. Data are representative of three independent 
experiments. (B) Silver staining of tyrosine-phosphorylated proteins 
from TEL-Syk–expressing cells. Total cellular lysates of indicated cells 
were subjected to immunoprecipitation with antiphosphotyrosine anti-
bodies (4G10). After SDS-PAGE and silver staining, bands marked with 
an asterisk were cut out and analyzed by mass spectrometry. Proteins 
identifi  ed are indicated next to the respective bands. Data are represen-
tative of two independent experiments. (C) The specifi  c Syk inhibitor 
R406 blocks substrate phosphorylation in TEL-Syk–transformed cells. 
Shown is an immunoblot analysis of TEL-Syk–transformed cells treated 
with the Syk inhibitors R406 (2 μM) or piceatannol (50 μM), with the 
BCR-Abl inhibitor STI-571 (2 μM), or with the Src family kinase inhibitor 
PP2 (5 μM) for the indicated times. Data are representative of fi  ve inde-
pendent experiments.2834  SYK KINASE IS A PROTOONCOGENE | Wossning et al.
We next tested the eff  ect of the Syk inhibitor R406 on 
the proliferation of TEL-Syk–transformed pre–B cells in 
  vitro. To this end, we examined the DNA content as an 
  indicator for the cell cycle status of TEL-Syk–transformed 
pre–B cells with and without R406 treatment. In untreated 
cultures,  51% of the cells were in S/G2 phase of the cell 
cycle and were thus proliferating (Fig. 5 A). However, upon 
treatment with R406, only 4% were proliferating and the 
majority of the cells (96%) was in G1 phase, whereas neither 
treatment with STI-571 nor PP2 reduced the proliferation of 
TEL-Syk–transformed cells (Fig. 5 A). Treatment with R406 
also moderately aff  ected proliferation of BCR-Abl–transformed 
cells, as seen by the reduction from 41 to 29% of cells in 
S/G2 (Fig. 5 A). On the other hand, treatment with STI-571 
reduced the proliferation of BCR-Abl–transformed cells effi   -
ciently, as >95% of these cells stop cycling, whereas TEL-
Syk–transformed cells were not aff  ected (Fig. 5 A).
In summary, these data show that the proliferation of 
TEL-Syk–transformed cells is dependent on Syk kinase activ-
ity and that inhibiting Syk activity blocks the proliferation of 
transformed cells.
Inhibition of Syk induces differentiation 
of TEL-Syk–transformed cells
Proliferation and diff   erentiation of pre–B cells are tightly 
regulated processes that often interfere with each other. 
Therefore, we tested whether TEL-Syk–transformed pre–B 
cells are blocked in diff   erentiation, similar to BCR-Abl–
transformed cells, and whether inhibition of Syk activity re-
leases this block and allows diff  erentiation from pre–B cells to 
Figure 5.  The Syk inhibitor R406 blocks proliferation and induces 
differentiation of TEL-Syk–transformed cells. (A) Syk inhibition blocks 
proliferation. Histograms showing the DNA content of TEL-Syk– or BCR-
Abl–transformed cells treated for 36 h with DMSO, 2 μM of the Syk in-
hibitor R406, or 2 μM of the Abl inhibitor STI-571. TEL-Syk– but not 
BCR-Abl–transformed cells were also treated with 5 μM of the Src family 
kinase inhibitor PP2. Data are representative of more than fi  ve indepen-
dent experiments. (B) TEL-Syk blocks pre–B cell differentiation. Pre–B cells 
expressing GFP, TEL-Syk, or BCR-Abl were cultured for 3 d in the absence 
of IL-7 and analyzed for the expression of κ L chain by FACS. Data are 
representative of three independent experiments. (C) Inhibition of TEL-Syk 
with R406 induces differentiation. FACS analysis of κ L chain expression 
on TEL-Syk– or BCR-Abl–transformed cells treated for 3 d with either 
2 μM R406 or 2 μM STI-571. Data are representative of two independent 
experiments. Numbers represent the percentage of cells in the indicated 
quadrant or gate.JEM VOL. 203, December 25, 2006  2835
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immature B cells. Indeed, pre–B cells transformed by BCR-
Abl or TEL-Syk poorly diff  erentiated into immature, κ L 
chain–expressing B cells upon withdrawal of IL-7 (Fig. 5 B), 
whereas treatment with STI-571 or R406 induced diff  eren-
tiation of the respective cells, as demonstrated by κ L chain 
expression (Fig. 5 C).
However, although cell cycle analyses suggested a mod-
erate eff  ect of R406 on BCR-Abl–transformed cells, R406 
treatment failed to induce κ L chain expression in these cells 
(Fig. 5 C). This discrepancy may be explained by the fact that 
Ig gene recombination, which is a prerequisite for L chain 
expression, is often nonproductive and, thus, does not lead 
to protein expression. To monitor the activation of diff  er-
entiation more effi   ciently, we constructed a recombination 
reporter plasmid with an inverted GFP cassette fl  anked by 
recombination signal sequences (RSS) from the κ L chain 
locus. Induction of diff  erentiation leads to activation of the 
recombination machinery and subsequent recombination 
between the two RSS, thereby inverting the GFP cassette 
and allowing its expression from the nearby promoter (Fig. 
6 A). We generated TEL-Syk– and BCR-Abl–transformed 
pre–B cells containing the GFP recombination reporter plas-
mid and measured GFP expression after treatment with ei-
ther R406 or STI-571 for 72 h (Fig. 6 B). All cells from 
TEL-Syk–transformed cultures treated with R406 showed a 
reduction in size, and 53% of the cells were GFP+, demon-
strating R406-induced diff  erentiation. After prolonged treat-
ment with R406, all cells died (unpublished data). Treatment 
with either STI-571 or DMSO did not lead to diff  erentiation 
of these cells, as seen by unchanged cell size and the lack of 
GFP expression (Fig. 6 B).
On the other hand, BCR-Abl–transformed cells diff  eren-
tiated effi   ciently upon treatment with STI-571, as demon-
strated by 42% GFP+ cells. In addition, the GFP recombination 
reporter confi  rmed the minor eff  ect of R406 on BCR-Abl–
transformed cells, as 4% of these cells turned GFP+ upon 
R406 treatment (Fig. 6 B).
In summary, these data show that counteracting Syk-
  induced proliferation by inhibiting Syk kinase activity induces 
diff  erentiation of pre–B cells into immature, κ L chain–
  expressing B cells.
The proliferation of c-Myc–transformed cells 
depends on Syk
The experiments presented in the previous sections suggest 
that Syk is a protooncogene that can promote pre–B cell 
transformation and cancer development. As cancer cells are 
often characterized by elevated expression levels of the tran-
scription factor c-Myc (15, 16), we analyzed c-Myc expression 
in Syk-transformed pre–B cells. Western blot analysis showed 
that, similar to BCR-Abl–transformed cells (38, 39), c-Myc 
expression was elevated in Syk- or TEL-Syk–transformed cells 
compared with cells expressing only GFP (Fig. 7 A).  Treatment 
of TEL-Syk–transformed cells with R406, but not with 
STI-571, decreased the expression of c-Myc, indicating that 
Syk is involved in c-Myc regulation (Fig. 7 A).
To investigate whether Syk-induced up-regulation of 
c-Myc is suffi   cient for transformation, we retrovirally ex-
pressed c-Myc–IRES–GFP in pre–B cells. Upon withdrawal 
of IL-7 from the culture medium, only c-Myc–expressing 
GFP+ pre–B cells survived (Fig. S2 A, available at http://
www.jem.org/cgi/content/full/jem.20060967/DC1). Fur-
thermore, injection of the c-Myc–transformed pre–B cells 
into RAG-2/γC−/− mice induced leukemia, demonstrat-
ing the oncogenic capacity of c-Myc (Fig. S2 A). We then 
treated the c-Myc–transformed cells with R406 and STI-571 
and analyzed proliferation by monitoring the DNA content. 
c-Myc–transformed cells were extremely sensitive to Syk 
inhibition, as observed by a reduction of proliferating cells 
from 33% in untreated cultures to 6% in cultures treated with 
R406 (Fig. 7 B). Furthermore, PP2-mediated inhibition of 
Src family kinases, which were shown to participate in the 
pre-BCR–dependent activation of Syk (40–42), reduced the 
proliferation of cells transformed by c-Myc (Fig. S2 B). On 
the other hand, treatment with STI-571 did not aff  ect prolif-
eration (Fig. 7 B). These data suggest that c-Myc–transformed 
cells require constitutive proliferation signals mediated by Syk. 
Because the pre-BCR is the main focus for Syk activation 
Figure 6.  A GFP-based system to measure Syk kinase inhibition. 
(A) Structure of the recombination reporter plasmid. Induction of RAG-1/2 
expression by differentiation-inducing stimuli leads to recombination of 
the two RSS (black triangles) fl  anking the inverted GFP cDNA. Flipping the 
GFP cassette brings the start codon close to the LTR, thereby enabling GFP 
expression. (B) FACS analysis showing GFP expression in pre–B cells 
  transformed by TEL-Syk or BCR-Abl and containing the recombination 
reporter plasmid. Cells were treated for 3 d with 2 μM R406 or 2 μM 
STI-571. Data are representative of three independent experiments. 
  Numbers represent the percentage of cells in the indicated quadrant. 
FSC, forward scatter; LTR, long terminal repeat.2836  SYK KINASE IS A PROTOONCOGENE | Wossning et al.
in pre–B cells, we examined whether the presence of the 
pre-BCR is required for c-Myc–induced pre–B cell trans-
formation. Therefore, we retrovirally expressed c-Myc 
in RAG-2−/− or Ig-α−/− pro–B cells, both of which lack 
pre-BCR expression. Remarkably, neither RAG-2−/− nor
Ig-α−/− pro–B cells could be transformed by c-Myc over-
expression (Fig. 7 C and not depicted). Even though 
Ig-α−/− cells expressing c-Myc showed a slightly prolonged 
survival in the absence of IL-7, they failed to proliferate and 
did not give rise to stable cell lines (Fig. 7 C). However, 
reconstitution of pre-BCR expression by retroviral expres-
sion of Ig-α led to strong expansion of c-Myc–expressing 
cells that yielded stable IL-7–independent lines (Fig. 7 C). 
These data demonstrate that pre-BCR signaling is required 
for the proliferation of c-Myc–transformed cells. In line 
with this, reconstitution of pre-BCR expression in Ig-α−/− 
cells increased the overall phosphotyrosine levels, whereas 
treatment with R406 reduced the overall phosphorylation 
in pre-BCR–expressing c-Myc–transformed cells (Fig. S2 C 
and not depicted).
Collectively, these data demonstrate that Syk-mediated 
pre-BCR signals are also required for the proliferation of 
Figure 7.  Transformation by Syk induces c-Myc up-regulation in 
pre–B cells. (A, left) Syk-transformed pre–B cells show augmented 
c-Myc expression. Immunoblot analysis of pre–B cells transduced with 
IRES-GFP vectors for the expression of GFP, Syk, TEL-Syk, or BCR-Abl. 
Data are representative of four independent experiments. (right) Inhibi-
tion of Syk decreases c-Myc expression in TEL-Syk–transformed cells. 
Immunoblot analysis of pre–B cells transformed by TEL-Syk treated with 
DMSO, 2 μM STI-571 for 2 d, or 2 μM R406 for 1, 1.5, and 2 d, as indi-
cated. Data are representative of two independent experiments. (B) Prolif-
eration of c-Myc–transformed pre–B cells depends on Syk activity. 
Histograms showing DNA content of c-Myc–transformed cells that were 
treated for 36 h with DMSO, 2 μM R406, or 2 μM STI-571. Data are rep-
resentative of more than fi  ve independent experiments. (C) Pre-BCR 
  expression is required for the transformation of Ig-α−/− pro–B cells by 
c-Myc. FACS profi  les show Ig-α−/− pro–B cells (left) or Ig-α−/− cells 
  reconstituted with Ig-α (right). Cells were retrovirally transduced with 
IRES-GFP vectors expressing either GFP alone or c-Myc, cultured in the 
absence of IL-7, and analyzed at days 1, 6, and 9 after transduction. 
Numbers represent the percentage of cells in the indicated quadrant or 
gate. FSC, forward scatter.JEM VOL. 203, December 25, 2006  2837
ARTICLE
tumorigenic cells transformed by other oncogenes, increas-
ing the potential of Syk as suitable target for the treatment 
of leukemia.
D  I  S  C  U  S  S  I  O  N 
The data presented in this study suggest that the tyrosine ki-
nase Syk is involved in pre–B cell transformation and leuke-
mia development. By comparing Syk to the tumor suppressor 
SLP-65, we show that Syk does not reduce pre–B cell prolif-
eration but rather transforms pre–B cell lines in a manner 
  dependent on Syk kinase activity. Our results indicate that 
Syk-dependent transformation may be induced either by 
mutations directly aff  ecting the Syk gene or by mutations 
that depend on Syk activity to transform particular cells. 
  Although this implies that Syk is a protooncogene, some pre-
vious studies suggested a tumor suppressor role for Syk. For 
instance, Syk was not detected in invasive breast carcinoma 
tissues and seemed to be required for the suppression of 
tumor growth and metastasis in this cancer disease (27, 28). 
However, extended analysis of more breast cancer samples 
could not confi  rm these results, and an earlier report even 
demonstrated a correlation between Syk expression and 
breast cancer development, arguing against a tumor suppres-
sor role for Syk (32, 43). In contrast, several lines of evidence 
indicate that Syk is a protooncogene. In agreement with this, 
recent studies show that Syk is expressed and constitutively 
phosphorylated in samples from ALL patients and that Syk 
gene amplifi  cation is found in mantle cell lymphomas (21–23). 
Furthermore, activation of Syk by ectopic expression of 
ITAM-bearing proteins was shown to transform fi  broblasts, 
whereas counteracting Syk activity by pharmaceutical inhibi-
tion or expression of the regulatory phosphatase PTPROt 
was shown to inhibit proliferation of B lymphoma cells (24, 
26, 44). Collectively, these data strongly suggest that deregu-
lation of Syk is involved in malignant transformation and 
cancer development in humans and that expression and acti-
vation of Syk must be tightly controlled to allow proper sig-
naling and prevent transformation. Consistent with this, we 
show that overexpression of Syk is not suffi   cient to transform 
freshly isolated BM-derived pre–B cells, most likely because 
these cells contain the appropriate mechanisms to regulate 
Syk activity. On the other hand, several immortalized pre–B 
cell lines could be effi   ciently transformed by Syk, presumably 
owing to preexisting mutations that may infl   uence cell 
growth and facilitate transformation. Indeed, cell lines that 
could be easily transformed by Syk, although dependent on 
IL-7 as a growth factor, survived slightly longer in the ab-
sence of IL-7 than those lines that did not become growth 
factor–independent by overexpression of Syk (unpublished 
data). It is conceivable that mutations in genes regulating Syk 
activity provide a suitable background to allow Syk-mediated 
transformation. One example for a negative regulator of Syk 
is the adaptor protein Cbl. Upon phosphorylation by Syk, 
Cbl interacts with several molecules, including nonreceptor 
protein tyrosine kinases and adaptor proteins (45–48). How-
ever, Cbl also selectively binds to activated Syk via its RING 
fi   nger domain, thereby targeting Syk to ubiquitinylation-
  mediated degradation (49, 50). Thus, Cbl-dependent degra-
dation prevents sustained activation of signaling pathways 
involved in Syk-induced proliferation. Consequently, Cbl−/− 
mice develop splenomegaly, and the viral form v-Cbl lacking 
the RING fi  nger domain is a potent oncogene (51–53).
The adaptor protein SLP-65 is, although more indirectly, 
also involved in the regulation of Syk. Upon activation, Syk 
phosphorylates SLP-65, thereby leading to the formation of a 
signaling complex that subsequently induces internalization 
of the pre-BCR. This mechanism prevents sustained activa-
tion of Syk by ITAM-bearing pre-BCR complexes expressed 
on the cell surface and, consequently, stops proliferation and 
enables diff  erentiation. Hence, loss of SLP-65 leads to the 
expression of high amounts of pre- BCR on the cell surface, 
thereby providing constant proliferation signals mediated by 
Syk. In line with this,  6% of SLP-65−/− mice develop leu-
kemia, and loss of SLP-65 expression was shown in human 
leukemia disease (11, 12).
In addition to mutations that modulate Syk activity indi-
rectly, other mutations may directly aff  ect Syk expression or 
function. One example is the TEL-Syk fusion protein that 
was originally isolated from a patient with myelodysplastic 
syndrome (18). In TEL-Syk, the dimerization domain of the 
transcription factor TEL is fused to the linker region of Syk, 
and TEL-induced dimerization is thought to augment Syk 
autophosphorylation, thereby leading to constitutive activa-
tion (18, 19). A further translocation isolated from 5 out of 30 
tested patients with heterogeneous peripheral T cell lym-
phoma fuses the N-terminal PH domain and the proline-rich 
Tec homology domain of ITK to the linker region of Syk (20). 
Although the breakpoints are not identical in TEL-Syk and 
ITK-Syk fusions, they are within the same region of the Syk 
gene, suggesting that this part is a hot spot for chromosomal 
translocations. The exact mechanism by which these fusion 
proteins induce cellular transformation and leukemia devel-
opment remains to be elucidated. However, we found the 
lipid-modifying enzymes PLCγ2 and PI3-K to be constitu-
tively phosphorylated upon Syk-induced transformation. 
Both molecules were shown to be direct substrates of Syk 
and are involved in the activation of survival- and prolifera-
tion-inducing pathways, suggesting that transformation by 
Syk, at least partially, depends on these enzymes (19, 54, 55). 
In particular, transformation by ITK-Syk might be explained 
by a PI3-K–dependent mechanism, where the PH domain of 
ITK mediates the recruitment of the ITK-Syk fusion protein 
to the plasma membrane by binding to phosphatidylinositol 
(3,4,5)P3. This would bring the Syk kinase domain into the 
proximity of membrane-associated PI3-K, which, upon acti-
vation by Syk, catalyzes the production of more phosphatidyl
inositol(3,4,5)P3, thereby establishing a positive feedback 
  activation of both Syk and PI3-K. Activation of the PI3-K 
pathway was previously shown to up-regulate expression of 
the transcription factor c-Myc in B lymphocytes (56). In 
agreement with the constitutive phosphorylation of PI3-K, 
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cells, suggesting that up-regulation of c-Myc is a key event in 
Syk-induced transformation. However, our data also show 
that elevated expression of c-Myc is not suffi   cient for the 
transformation of pre–B cells and that additional pre-BCR–
derived proliferation signals mediated via Syk are involved. 
Specifi   cally, we show that reconstitution of pre-BCR 
  expression increases the overall tyrosine phosphorylation in 
Ig-α−/− cells and allows c-Myc–mediated transformation, 
whereas blocking pre-BCR signaling by inhibition of Syk or 
Src family kinases prevents proliferation. On the other hand, 
we show that transformation by TEL-Syk does not depend 
on pre-BCR expression and Src kinases, suggesting that con-
stitutively active TEL-Syk, besides up-regulating c-Myc,  mimics 
pre-BCR–derived proliferation signals.
Although our data show that Syk is required for pro-
liferation and that deregulated Syk activity results in pre–B 
cell transformation, they do not rule out a role for Syk in 
diff  erentiation. In fact, by phosphorylating SLP-65, Syk 
is involved in the activation of pre–B cell diff  erentiation. 
Defective SLP-65 activation may explain the developmental 
block of Syk−/− pre–B cells (57–59) and their increased in 
vitro proliferation rate as compared with WT cells (60). In 
these Syk−/− pre–B cells, ZAP-70, a Syk family kinase, may 
replace Syk in inducing proliferation. However, additional 
experiments are required to determine the proliferation rate 
of Syk−/− and Syk−/−/ZAP-70−/− pre–B cells compared 
with WT counterparts.
Together with previously published studies, our data sug-
gest that deregulated Syk kinase activity may be a frequent 
mechanism for the transformation of lymphocytes and the 
development of leukemia. Moreover, we demonstrate that 
Syk kinase activity is required for the proliferation of pre–B 
cells transformed by other oncogenes such as c-Myc and 
that treatment of those tumorigenic cells with the novel Syk 
  kinase inhibitor R406 blocks proliferation. Therefore, specifi  c 
kinase inhibitors for Syk may provide a potential approach 
for the treatment of leukemia in human.
MATERIALS AND METHODS
Mice. RAG-2/γC−/− mice (61) were used for adoptive transfer experi-
ments. BM cells from BALB/c mice were retrovirally transduced with the 
respective vectors, and 1–5 × 106 cells were injected into RAG-2/γC−/− 
mice 1 wk after transduction. When showing the fi  rst symptoms of disease, 
mice were killed for analysis of spleen and BM. RAG-2/γC−/− and BALB/
c (WT) mice were bred at the animal facility of the Max-Planck-Institute for 
Immunobiology. Animal experiments were done in compliance with guide-
lines of the German law and the Max-Planck-Institute for Immunobiology.
Cell culture. Cell lines were grown in Iscove’s medium (Biochrom) 
  containing 10% FCS (Vitromex), 2 mM l-glutamine, 100 U/ml penicillin, 
100 U/ml streptomycin (Invitrogen), and 50 μM 2-mercaptoethanol. For 
culture of IL-7–dependent cells, culture supernatant from J558L cells stably 
transfected with a mouse IL-7 expression vector was added. BM cells were 
isolated from 6–12-wk-old BALB/c mice and kept in culture for at least 1 d 
before being subjected to experiments.
Plasmids and retroviral transduction. Retroviral transductions were 
performed as described previously (62). The retroviral expression vector 
pMIG contains an IRES followed by the GFP cDNA. pMIG-BCR-Abl was 
a gift from W.S. Pear (University of Pennsylvania, Philadelphia, PA). pMIG-
Syk, pMIG-TEL-Syk, and pMIG-Myc were generated by insertion of PCR 
fragments containing the complete open reading frame of human Syk, TEL-
Syk, or c-Myc into pMIG. Mutant TEL-SykK402A was generated by PCR 
using primers carrying the desired mutation and primers covering the 5′ and 
3′ ends of TEL and Syk, respectively. Vectors encoding TEL-Syk and 
BCR-Abl without fl  uorescence markers were generated by excision of the 
IRES-GFP sequence and religation of the respective vectors. For construc-
tion of the recombination reporter plasmid, we ligated a PCR fragment in-
cluding both 5′ and 3′ RSS amplifi  ed from the vector pJH288 (63) into the 
retroviral expression vector pMOWS containing a puromycin resistance 
gene for selection (62). GFP cDNA was ligated in between the RSS in 
  reverse orientation.
Flow cytometry and cell sorting. Cells were stained for FACS with anti-
CD19 (BD Biosciences), anti-κ (Southern Biotechnology Associates, Inc.), 
anti-IgM (Jackson ImmunoResearch Laboratories), and anti-SLC/HC 
(SL156; a gift from Ton Rolink, University of Basel, Basel, Switzerland). For 
cell cycle analysis, cells were fi  xed in 70% ethanol overnight and subse-
quently incubated in PBS containing 1.6 μg/ml propidium iodide and 
1 μg/ml RNase for 30 min at 37°C. Acquisition was performed with the 
LSR II (Becton Dickinson). Transduced GFP+ cells were sorted to a purity 
>99% using a high-speed sorter (MoFlo; Cytomation).
Cell lysis and immunoblotting. TEL-Syk– and BCR-Abl–expressing 
cells were grown in medium without IL-7. GFP- and TEL-SykK402A–
  expressing cells were sorted for GFP expression, expanded in medium con-
taining IL-7, and cultured for 24 h in the absence of IL-7. Cells were lysed 
in 5 μl lysis buff  er (50 mM Tris-HCl, pH 7.4, 1% Triton [Sigma-Aldrich], 
137.5 mM NaCl, 1% glycerol, 1 mM Na-orthovanadate, 0.5 mM EDTA, 
pH 8, and protease inhibitor cocktail [Sigma-Aldrich]) per 105 cells. Lysates 
were separated on 10% SDS-polyacrylamide gels and transferred onto nitro-
cellulose membranes (Hybond; GE Healthcare). Membranes were blocked 
with 5% milk powder in PBT (PBS, 0.1% Tween 20) for 1 h. Primary anti-
bodies were diluted in PBT supplemented with 2% bovine serum albumin 
fraction V (BIOMOL Research Laboratories, Inc.), and secondary antibod-
ies were diluted in blocking solution. Immunoreactive proteins were de-
tected using a chemolumiscence detection system (ECL; GE Healthcare). 
Antibodies used were anti-Syk (4D10; Santa Cruz Biotechnology, Inc.), 
anti-Syk (N19; Santa Cruz Biotechnology, Inc.), anti–SLP-65 (generated in 
our lab), antiphosphotyrosine (4G10; Upstate Biotechnology), anti–α-actin 
(I-19; Santa Cruz Biotechnology, Inc.), anti–Ig-α (64), anti-cAbl (K-12; 
Santa Cruz Biotechnology, Inc.), and anti–c-Myc (9E10).
Application of kinase inhibitors. Syk inhibitor R406 (provided by Rigel 
Pharmaceuticals, Inc., San Francisco, CA), Abl inhibitor STI-571 (provided 
by Novartis, Basel, Switzerland), Src inhibitor PP2 (Calbiochem), and Syk 
inhibitor piceatannol (Sigma-Aldrich) were dissolved in DMSO. For treat-
ment, cells were cultured in medium containing 0.5% DMSO and either 
2 μM R406, 2 μM STI-571, 5 μM PP2, or 50 μM piceatannol.
Mass spectrometry. Immobilized antiphosphotyrosine antibody (4G10) 
was used to precipitate 106 nontransformed, Tel-Syk, and BCR-Abl–trans-
formed cells, respectively. Bound proteins were resolved by 10% SDS-PAGE 
and visualized by silver staining. Individual bands were excised and enzy-
matically digested with trypsin. Before LC-MS analysis, tryptic peptide mix-
tures were desalted using STAGE tips as described previously (65). Nanoscale 
LC (MDLC; GE Healthcare) was coupled to a 7-tesla linear ion-trap 
Fourier-transform ion cyclotron resonance mass spectrometer (LTQ-FT; 
Thermo Electron) equipped with a nanoelectrospray source (Proxeon). 
  Peptides were eluted from an analytical column by a linear gradient running 
from 2 to 60% (vol/vol) acetonitrile (in 0.5% acetic acid) with a fl  ow rate of 
250 nl/min in 35 min and sprayed directly into the aperture of the mass 
spectrometer. Information-dependent acquisition of MS, MS/MS, and MS3 
spectra was performed as described previously (66). Acquired spectra were JEM VOL. 203, December 25, 2006  2839
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then searched with Mascot (Matrix Science) against the human and mouse 
International Protein Index protein database (version 3.14, available at 
http://www.ebi.ac.uk/IPI/), to which we added frequently observed con-
taminants. Tryptic enzyme specifi  city with up to two missed cleavages was 
applied to all searches. Protein identifi  cations were further analyzed and 
manually verifi   ed by the use of MSQuant (available at http://msquant.
sourceforge.net).
Online supplemental material. Fig. S1 shows the reduction of Syk-
  induced overall tyrosine phosphorylation after treatment with R406, whereas 
tyrosine phosphorylation in BCR-Abl–transformed cells is unaff  ected by 
R406 treatment. Fig. S2 shows that overexpression of c-Myc leads to the 
transformation of pre–B cells and that pre-BCR signaling is required for 
c-Myc–induced transformation. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20060967/DC1.
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